Lupin gets FDA approval for budesonide inhalation suspension
MUMBAI, India and BALTIMORE, Md. — Pharma major Lupin announced that it has received approval for its budesonide inhalation suspension, 0.5 mg/2 mL single-dose ampules from the United States Food and Drug Administration to market a generic version of AstraZeneca Pharmaceuticals LP’s (AstraZeneca) Pulmicort Respules Inhalation Suspension, 0.5 mg/2 mL. Lupin’s budesonide inhalation suspension, 0.5
